Evidence map›Paper›PMID 28435221›Full record

ArticleDrug design, development and therapy2017

Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of

Cristiane França da Silva, Denise da Gama Jaén Batista, Julianna Siciliano de Araújo, Edézio Ferreira Cunha-Junior, Chad E Stephens, Moloy Banerjee, Abdelbasset A Farahat, Senol Akay, Mary K Fisher, David W Boykin and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review on Experimental Treatment Strategies AgainstJournal of experimental pharmacology · 2021
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Cristiane França da SilvaLaboratory of Cellular Biology.
Denise da Gama Jaén BatistaLaboratory of Cellular Biology.
Julianna Siciliano de AraújoLaboratory of Cellular Biology.
Edézio Ferreira Cunha-JuniorLaboratory of Biochemistry of Trypanosomatids, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Chad E StephensDepartment of Chemistry and Physics, Augusta University, Augusta.
Moloy BanerjeeDepartment of Chemistry, Georgia State University, Atlanta, GA, USA.
Abdelbasset A FarahatDepartment of Chemistry, Georgia State University, Atlanta, GA, USA.
Senol AkayDepartment of Chemistry, Georgia State University, Atlanta, GA, USA.
Mary K FisherDepartment of Chemistry and Physics, Augusta University, Augusta.
David W BoykinDepartment of Chemistry, Georgia State University, Atlanta, GA, USA.
Maria de Nazaré Correia SoeiroLaboratory of Cellular Biology.
Georgia State University · USFundação Oswaldo Cruz · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arylimidamides (AIAs), previously termed as reversed amidines, present a broad spectrum of activity against intracellular microorganisms. In the present study, three novel AIAs were evaluated in a mouse model of

Indexed as

Disease Models, AnimalAmidinesAnimalsChagas DiseaseDose-Response Relationship, DrugFemaleMaleMiceMolecular StructureParasitic Sensitivity TestsPhenotypeStructure-Activity RelationshipTrypanocidal AgentsTrypanosoma cruziAmidinesTrypanocidal AgentsarylimidamidesChagas diseaseexperimental chemotherapyin vivo assays

Identifiers

PMID28435221
PMCPMC5388221
OpenAlexW2604635671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.